Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Trial of Combination Immunotherapy With HER2/Neu Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients

NCT03014076 is registered in ClinicalTrials.gov with Cancer Insight, LLC as lead sponsor.

NCT NCT03014076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03014076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Trial of Combination Immunotherapy With HER2/Neu Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients
Lead sponsor
Cancer Insight, LLC
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2008
Completion date
January 31, 2017
Enrollment
30 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breastcancer